Skip to main content

Diprivan® (Propofol) injection, an anesthetic, is the company’s first smart-labeled product with radio frequency identification (RFID) technology and the 20 mL vial is now available in this enhanced presentation in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. Fresenius Kabi expects to introduce numerous other products with RFID technology in the coming year.

Diprivan® (Propofol) injection, an anesthetic, is the company’s first smart-labeled product with radio frequency identification (RFID) technology and the 20 mL vial is now available in this enhanced presentation in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. Fresenius Kabi expects to introduce numerous other products with RFID technology in the coming year.

Beginning in Q4 2020, Fresenius Kabi will introduce smartlabels with radio frequency identification (RFID) technology for medications frequently used in the operating room in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. The first products in the smartlabel portfolio are anesthesia and analgesia products in prefilled syringes and vials.

Beginning in Q4 2020, Fresenius Kabi will introduce smartlabels with radio frequency identification (RFID) technology for medications frequently used in the operating room in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. The first products in the smartlabel portfolio are anesthesia and analgesia products in prefilled syringes and vials.

Morphine Sulfate Injection is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes in MicroVault packaging. MicroVault packaging is designed to support the secure dispensing of controlled substances, for example via transparent hard plastic packaging allowing bar code scanning and visual inspection as well as a tamper evident seal.

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

Fresenius Kabi announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company`s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is an important achievement in the development of Fresenius Kabi’s biosimilar pipeline in the US. Fresenius Kabi also received acceptance for review of its regulatory submission for its pegfilgrastim biosimilar candidate from the European Medicines Agency this month. (* Neulasta® is a registered trademark of Amgen)

Subscribe to Fresenius Kabi